Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

This study has been completed.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center Identifier:
First received: June 10, 2004
Last updated: August 22, 2013
Last verified: August 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Schiller GJ, Sohn JP, Malone P, et al.: Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate- and advanced-stage multiple myeloma. [Abstract] Biol Blood Marrow Transplant 13 (2 Suppl 1): A-153, 57, 2007.